TI
TGTX icon

Trexquant Investment’s TG Therapeutics TGTX Stock Holding History

Trexquant Investment’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.35M Sell
152,005
-159,214
-51% -$6.52M 0.05% 508
2026
Q1 		$10.3M Sell
311,219
-201,235
-39% -$6M 0.07% 371
2025
Q4 		$15.3M Buy
512,454
+246,057
+92% +$8.04M 0.14% 190
2025
Q3 		$9.62M Buy
266,397
+233,202
+703% +$7.68M 0.1% 302
2025
Q2 		$1.19M Buy
+33,195
New +$1.24M 0.01% 1053
2024
Q4 		– Sell
-80,468
Closed -$1.88M – 1853
2024
Q3 		$1.88M Sell
80,468
-68,950
-46% -$1.51M 0.02% 837
2024
Q2 		$2.66M Buy
+149,418
New +$2.38M 0.04% 632
2024
Q1 		– Sell
-350,218
Closed -$5.98M – 1784
2023
Q4 		$5.98M Sell
350,218
-40,289
-10% -$468K 0.13% 198
2023
Q3 		$3.26M Buy
390,507
+246,022
+170% +$3.43M 0.08% 340
2023
Q2 		$3.59M Buy
+144,485
New +$3.73M 0.09% 300
2023
Q1 		– Sell
-386,467
Closed -$4.57M – 1767
2022
Q4 		$4.57M Buy
386,467
+351,098
+993% +$2.55M 0.13% 204
2022
Q3 		$209K Buy
+35,369
New +$232K 0.01% 1175
2020
Q1 		– Sell
-41,522
Closed -$461K – 1417
2019
Q4 		$461K Buy
+41,522
New +$316K 0.03% 588
2018
Q3 		– Sell
-21,522
Closed -$283K – 1190
2018
Q2 		$283K Sell
21,522
-64,421
-75% -$886K 0.02% 699
2018
Q1 		$1.22M Buy
85,943
+18,700
+28% +$239K 0.09% 363
2017
Q4 		$551K Buy
+67,243
New +$588K 0.06% 476
2016
Q3 		– Sell
-43,609
Closed -$264K – 1004
2016
Q2 		$264K Buy
+43,609
New +$355K 0.03% 706
2016
Q1 		– Sell
-23,950
Closed -$286K – 1173
2015
Q4 		$286K Buy
+23,950
New +$302K 0.03% 863
2015
Q3 		– Sell
-31,300
Closed -$519K – 1257
2015
Q2 		$519K Buy
+31,300
New +$496K 0.06% 606

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Trexquant Investment's TGTX Position: Q2 2026 in Review

Trexquant Investment reduced its TG Therapeutics (TGTX) stake by 51% in Q2 2026, selling an estimated $6.52M and leaving 152,005 shares worth $8.35M. The position accounts for 0.05% of the portfolio, ranked #508.

Trexquant Investment first reported a position in TGTX in Q2 2015 and has held it in 19 quarters since. The position peaked at $15.3M in Q4 2025. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Trexquant Investment held 152,005 shares of TG Therapeutics worth $8.35M as of Q2 2026.
  • Trexquant Investment sold 159,214 TG Therapeutics shares in Q2 2026, an estimated $6.52M.
  • TG Therapeutics made up 0.05% of Trexquant Investment's portfolio in Q2 2026, its #508 holding.
  • Trexquant Investment first reported a position in TG Therapeutics in Q2 2015 and has held it in 19 quarters since.
  • Trexquant Investment's TG Therapeutics position peaked at $15.3M in Q4 2025.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.